Celcuity Inc. (NASDAQ:CELC) Short Interest Update

Celcuity Inc. (NASDAQ:CELC) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 3,330,000 shares, a growth of 6.4% from the January 15th total of 3,130,000 shares. Based on an average daily volume of 283,600 shares, the days-to-cover ratio is currently 11.7 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Summit Investment Advisors Inc. increased its position in Celcuity by 49.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company’s stock valued at $45,000 after purchasing an additional 1,132 shares during the period. Acuta Capital Partners LLC lifted its stake in shares of Celcuity by 3.6% during the 3rd quarter. Acuta Capital Partners LLC now owns 46,600 shares of the company’s stock worth $695,000 after purchasing an additional 1,600 shares during the last quarter. Corebridge Financial Inc. lifted its stake in shares of Celcuity by 12.9% during the 4th quarter. Corebridge Financial Inc. now owns 16,256 shares of the company’s stock worth $213,000 after purchasing an additional 1,858 shares during the last quarter. nVerses Capital LLC bought a new stake in Celcuity during the third quarter valued at about $33,000. Finally, Prospera Private Wealth LLC purchased a new position in Celcuity in the third quarter valued at about $35,000. Institutional investors own 63.33% of the company’s stock.

Celcuity Trading Up 2.1 %

Shares of NASDAQ:CELC traded up $0.26 during trading on Monday, reaching $12.88. 148,960 shares of the company were exchanged, compared to its average volume of 225,983. The business’s fifty day simple moving average is $12.26 and its 200-day simple moving average is $14.10. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. Celcuity has a 12-month low of $10.35 and a 12-month high of $22.19. The firm has a market capitalization of $478.23 million, a PE ratio of -4.93 and a beta of 0.73.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. HC Wainwright restated a “buy” rating and set a $27.00 target price on shares of Celcuity in a research report on Friday, November 15th. Needham & Company LLC upped their price objective on Celcuity from $23.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $30.17.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.